Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672879 · ClinicalTrials.gov registry record · Phase 2
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT01672879 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 259 participants.
The verdict
NCT01672879, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH). It will consist of 2 phases: * Randomized Double-Blind Phase * Open-Label Phase (optional)
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL SIM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2012-10-29 |
| Est. Completion | 2017-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01672879
The ClinicalTrials.gov registry entry for NCT01672879 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01672879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01672879 about?
NCT01672879 is a clinical study titled "Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH". The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH). It will consist of 2 phases: * Randomized Double-Blind Phase * Open-Label Phase (optional)
What is the current status of trial NCT01672879?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2012-10-29. Estimated completion is 2017-01-03.
What interventions are being tested in trial NCT01672879?
The interventions under investigation include: Placebo (BIOLOGICAL), SIM (BIOLOGICAL).
Who is sponsoring clinical trial NCT01672879?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.